Floatz logo

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine

Hematopoietic Cell Transplant Recipient

City of Hope Medical CentervaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hematopoietic Cell Transplant Recipient cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2B
Fludarabine
Fred Hutchinson Cancer Center
Phase 2B
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2CCC
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2CCC
Monomethyl Fumarate
Fred Hutchinson Cancer Center
Phase 2CCC
wt1-sensitized allogeneic t-lymphocytes
Fred Hutchinson Cancer Center
Phase 1/2CCC

Same molecule, other indications

Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine is also rated in:

hematopoietic and lymphoid cell neoplasmDormant
B
Indicative ·
60 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
58 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →